The use of PARP inhibitors in patients with a variety of tumor types is backed by a growing body of research, and there is now strong justification for clinical trials of these agents in patients with prostate cancer.
More From BioPortfolio on "DNA Repair Defects Are Strong Targets for Therapeutic Development in Prostate Cancer"